Clinical Trial Update: PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354. [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 trial of Tibotec compounds TMC589337 and TMC589354 (single-dose escalation and multiple-dosing parts) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC589337
• TMC589354

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections | Phase 1 | Status: WITHDRAWN